our Premium Content: News alerts, weekly reports and conference planners

GENE:

TPM4 (Tropomyosin 4)

News alerts, weekly reports and conference planners

2ms

An Unusual High-Grade Sarcoma of the Kidney with TPM4::NTRK1 Fusion, CDKN2A/B Deletion, SDHD and NOTCH3 Variants: The First Case Report in Pediatric Population. (PubMed, Fetal Pediatr Pathol)

Based on these molecular findings, the diagnosis was confirmed as an NTRK-rearranged high-grade sarcoma with an unusual histomorphological phenotype. This case highlights novel molecular characteristics of NTRK-rearranged high-grade sarcoma and underscores the critical role of comprehensive molecular profiling in diagnosing challenging cases.

2 months ago

Journal

NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NOTCH3 (Notch Receptor 3) • NTRK (Neurotrophic receptor tyrosine kinase) • SDHD (Succinate Dehydrogenase Complex Subunit D) • TPM4 (Tropomyosin 4)

CDKN2A deletion • NTRK fusion

2ms

Integrating multi-omics and clinical features to model survival in epithelial ovarian cancer subtypes. (PubMed, Sci Rep)

Integrating multivariate predictive modeling with biological interpretation provides a comprehensive framework for personalized risk stratification and treatment decision-making in EOC. The identified prognostic biomarkers, such as TPM4, SDHD, MUC16, and BCL6, represent potential targets for future studies and therapeutic interventions.

2 months ago

Journal

TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • BCL6 (B-cell CLL/lymphoma 6) • WT1 (WT1 Transcription Factor) • MUC16 (Mucin 16, Cell Surface Associated) • FAT3 (FAT Atypical Cadherin 3) • ZFHX3 (Zinc Finger Homeobox 3) • FAT4 (FAT Atypical Cadherin 4) • CSMD3 (CUB And Sushi Multiple Domains 3) • HOXA11 (Homeobox A11) • SDHD (Succinate Dehydrogenase Complex Subunit D) • TPM4 (Tropomyosin 4)

TP53 mutation • PIK3CA mutation • PTEN mutation • ARID1A mutation

3ms

Biomimetic core-shell breast cancer models using alginate, gelatin, and collagen I: simulating the tumor matrix for drug evaluation. (PubMed, Int J Biol Macromol)

Breast cancer cells proliferated in the core of all prototypes designed, forming spheroids and cell aggregates with a high resistance to doxorubicin. The addition of Collagen I to the developed model enabled the upregulation of malignancy markers (Col1A1, Ki67, FOXC2, SNAI1, NFKB1, WWTR1), invasion markers (WASL, ACTA1, MYO1E, TPM4, PODXL, ITGA2, ITGA5, MENA, EGFR, CDC42), and drug resistance markers (ABCG2, CYP1A1, BAX, HSP90AA1) occurring in vivo. The developed 3D in vitro model can clarify the contribution of the extracellular matrix to the tumor outcome and drug efficacy by replicating some key characteristics of breast tumors, establishing a novel tool for chemotherapeutic agents and drug screening.

3 months ago

Preclinical • Journal

EGFR (Epidermal growth factor receptor) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • BAX (BCL2-associated X protein) • COL1A1 (Collagen Type I Alpha 1 Chain) • WWTR1 (WW Domain Containing Transcription Regulator 1) • CDC42 (Cell Division Cycle 42) • PODXL (Podocalyxin) • SNAI1 (Snail Family Transcriptional Repressor 1) • TPM4 (Tropomyosin 4) • ACTA1 (Actin Alpha 1, Skeletal Muscle) • CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • ITGA2 (Integrin Subunit Alpha 2) • ITGA5 (Integrin Subunit Alpha 5) • FOXC2 (Forkhead Box C2)

doxorubicin hydrochloride

4ms

Isoform Specificity of a Compound Targeting Actin Filaments Containing Tropomyosin Tpm1.8/1.9. (PubMed, Cytoskeleton (Hoboken))

Tpm1.8/1.9 organisation becomes dispersed between 12- and 18-hour exposure to 189-3, and the organisation of Tpm1.8/1.9 returns within 4 h of drug washout. We conclude that the amino acid sequence differences located at 7 positions in the first 19 residues of these isoforms provide sufficient specificity to generate compounds that target Tpm1.8/1.9 alone.

4 months ago

Journal

TPM4 (Tropomyosin 4)

6ms

The role of glycolytic condensates in the cellular stress response during cancer progression. (PubMed, Adv Biol Regul)

We discuss the role of scaffold molecules, such as TPM4, F-actin, and RNA, in mediating condensate assembly and stabilization. A deeper understanding of the regulation and function of glycolytic condensates could reveal new vulnerabilities in tumor metabolism and generate strategies to hinder cancer cell adaptation to stress.

6 months ago

Review • Journal

TPM4 (Tropomyosin 4)

7ms

Hypoxia upregulate TPM4 expression to strengthen epithelial-mesenchymal transition that promotes lymph node metastasis of papillary thyroid cancer. (PubMed, J Cancer)

Functional assays demonstrated that TPM4 enhanced cellular invasion and migration capabilities. Our findings illuminate a novel mechanism whereby the hypoxic tumor microenvironment promotes lymph node metastasis in PTC through TPM4-mediated activation of EMT signaling, providing new insights into LNM of PTC.

7 months ago

Journal

TPM4 (Tropomyosin 4)

9ms

Case Report: Clinical response of ensartinib for inflammatory myofibroblastic tumor of the urinary bladder with multiple metastases and TPM4-ALK fusion. (PubMed, Front Oncol)

Ensartinib may provide a new therapeutic direction with promising efficacy and an acceptable safety profile for IMTUB with ALK fusion. Further clinical investigation is needed to identify its efficacy and safety.

9 months ago

Journal

ALK (Anaplastic lymphoma kinase) • TPM4 (Tropomyosin 4)

ALK fusion

Ensacove (ensartinib)

9ms

Identification of a Biomarker Panel in Extracellular Vesicles Derived From Non-Small Cell Lung Cancer (NSCLC) Through Proteomic Analysis and Machine Learning. (PubMed, J Extracell Vesicles)

Western blotting results confirm upregulation trends for MVP, GYS1, SERPINA3, HECTD3, SERPING1 and APOD, and TPM4 is downregulated in EVs of NSCLC patients compared with healthy individuals. These findings highlight the potential of this biomarker panel for the clinical diagnosis of NSCLC.

9 months ago

Journal

PVR (PVR Cell Adhesion Molecule) • MVP (Major Vault Protein) • TPM4 (Tropomyosin 4) • SERPINA3 (Serpin Family A Member 3)

11ms

TPM4 influences the initiation and progression of gastric cancer by modulating ferroptosis via SCD1. (PubMed, Clin Exp Med)

TPM4 is a promising target for new diagnostic, prognostic, and therapeutic strategies for GC. Downregulation of TPM4 inhibits GC cell growth and induces ferroptosis by suppressing SCD1 expression.

11 months ago

Journal

TPM4 (Tropomyosin 4) • SCD (Stearoyl-CoA Desaturase)

11ms

Plasma-Derived Exosomal i-tRF-LeuCAA as Biomarker for Glioma Diagnosis and Promoter of Epithelial-Mesenchymal Transition via TPM4 Regulation. (PubMed, CNS Neurosci Ther)

i-tRF-LeuCAA could be served as a non-invasive biomarker in the diagnosis and prognosis of glioma. i-tRF-LeuCAA may indirectly regulate TPM4 expression and influence epithelial-mesenchymal transition, which may promote glioma progression.

11 months ago

Journal

TPM4 (Tropomyosin 4)

12ms

Cutaneous Hemangioma With Epithelioid Features Harboring TPM3/4::ALK Fusions: A Distinct Entity or a Molecular Variant of Epithelioid Hemangioma? (PubMed, Am J Surg Pathol)

We conclude that cutaneous hemangiomas with epithelioid features harboring TPM3/4::ALK fusions show consistent morphologic, immunophenotypic, and molecular genetic features. It remains to be determined whether this neoplasm represents a distinct entity or a molecular variant of epithelioid hemangioma.

12 months ago

Journal

ALK (Anaplastic lymphoma kinase) • TPM3 (Tropomyosin 3) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • TPM4 (Tropomyosin 4)

ALK fusion